GlycoMimetics to Present at Upcoming Healthcare Investor Conferences

- November 10th, 2016

GlycoMimetics today announced that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week.

GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week, as follows:

STIFEL 2016 HEALTHCARE CONFERENCE
WHEN: NOVEMBER 15,
2016 AT 4:30 PM ET
WHERE: NEW YORK, NY, USA

JEFFERIES 2016 LONDON HEALTHCARE CONFERENCE
WHEN: NOVEMBER
17, 2016 AT 1:20 PM GMT
WHERE: LONDON, UK

To access the live webcast and subsequent archived recordings for the
presentation, please visit the GlycoMimetics website at www.glycomimetics.com.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on
cancer and sickle cell disease. GlycoMimetics’ most advanced drug
candidate, rivipansel, a pan-selectin antagonist, is being developed for
the treatment of vaso-occlusive crisis in sickle cell disease and is
being evaluated in a Phase 3 clinical trial being conducted by its
strategic collaborator, Pfizer. GlycoMimetics’ wholly-owned drug
candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an
ongoing Phase 1/2 clinical trial as a potential treatment for AML and in
a Phase 1 clinical trial in multiple myeloma. GlycoMimetics has also
recently initiated a clinical trial with a third drug candidate,
GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is
located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply